Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Teresa Morán et al.|The Lancet Oncology|2012Cited by 5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerRafael Rosell, Miquel Tarón, Teresa Morán et al.|New England Journal of Medicine|2009Cited by 2.4k
Genetic Variants Associated With Cancer Therapy–Induced CardiomyopathyPablo García‐Pavía, Bonnie Ky, Yuri Kim et al.|Circulation|2019Cited by 346
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibitionAlberto Cruz‐Bermúdez, Mariano Provencio|Free Radical Biology and Medicine|2019Cited by 215
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signalingAlberto Cruz‐Bermúdez, Mariano Provencio|Free Radical Biology and Medicine|2018Cited by 140